Aplastic Anemia (AA) is a serious hematological disease characterized by bone marrow failure and pancytopenia, which is difficult to treat, particularly in refractory and relapsed cases. This review will consider the recent developments on the treatment of Severe Aplastic Anemia (SAA), with particular emphasis on new therapeutic modalities and their possible role in enhancing patient outcomes. We discuss the effectiveness and safety of Salvage Immunosuppressive Therapy (IST), Hematopoietic Stem Cell Transplantation (HSCT), and newer agents like Thrombopoietin Receptor Agonists (TPO-RAs) such as eltrombopag. Moreover, we also address the contribution of alternative donor HSCT, including haploidentical and umbilical cord blood transplantations, and the prospects of emerging immunomodulatory drugs. The present review is intended to give a detailed account of existing treatment options, identify active research areas, and provide practical recommendations to clinicians dealing with refractory and relapsed SAA, and it underlines the necessity of individualized, mechanism-driven strategies to maximize patient care.
Lyu et al. (2026) studied this question.